Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Connor MP, Loren AW, Hexner EO, Martin ME, Gill SI, Luger SM, Mangan JK, Perl AE, McCurdy SR, Pratz KW, Timlin C, Freyer CW, Carulli A, Catania C, Smith J, Hollander L, Zebrowski AM, Stadtmauer EA, Porter DL, Frey NV. Connor MP, et al. Among authors: pratz kw. Transplant Cell Ther. 2023 Feb;29(2):113-118. doi: 10.1016/j.jtct.2022.10.027. Epub 2022 Nov 4. Transplant Cell Ther. 2023. PMID: 36336258 Free article.
Fibrinogen consumption and use of heparin are risk factors for delayed bleeding during acute promyelocytic leukemia induction.
Hambley BC, Norsworthy KJ, Jasem J, Zimmerman JW, Shenderov E, Webster JA, Showel MM, Gondek LP, Dalton WB, Prince G, Gladstone DE, Streiff MB, Pratz KW, Gojo I, Ghiaur G, Levis MJ, Smith BD, DeZern AE. Hambley BC, et al. Among authors: pratz kw. Leuk Res. 2019 Aug;83:106174. doi: 10.1016/j.leukres.2019.106174. Epub 2019 Jun 21. Leuk Res. 2019. PMID: 31255938 Clinical Trial. No abstract available.
4EBP1/c-MYC/PUMA and NF-κB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells.
Yun S, Vincelette ND, Knorr KL, Almada LL, Schneider PA, Peterson KL, Flatten KS, Dai H, Pratz KW, Hess AD, Smith BD, Karp JE, Hendrickson AE, Fernandez-Zapico ME, Kaufmann SH. Yun S, et al. Among authors: pratz kw. Blood. 2016 Jun 2;127(22):2711-22. doi: 10.1182/blood-2015-02-629485. Epub 2016 Feb 25. Blood. 2016. PMID: 26917778 Free PMC article.
Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.
Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH. Karp JE, et al. Among authors: pratz kw. Clin Cancer Res. 2012 Dec 15;18(24):6723-31. doi: 10.1158/1078-0432.CCR-12-2442. Epub 2012 Oct 23. Clin Cancer Res. 2012. PMID: 23092873 Free PMC article. Clinical Trial.
Azacitidine and Venetoclax in AML. Reply.
DiNardo CD, Wang J, Pratz KW. DiNardo CD, et al. Among authors: pratz kw. N Engl J Med. 2020 Nov 19;383(21):2088-2089. doi: 10.1056/NEJMc2029153. N Engl J Med. 2020. PMID: 33207106 No abstract available.
96 results